The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index; 39 of the 79 sources its claims cite were checked for support.
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease
Open accessAbstract
Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of SCD due to AD. Additionally, the interaction of SCD with other risk factors for dementia due to AD, such as age and the Apolipoprotein E (ApoE) ɛ4 status, has also been described. Finally, the possible explanations for the inconsistent and heterogeneous neuroimaging findings observed in individuals with SCD are discussed, along with future directions. Overall, the literature reveals a preferential vulnerability of AD signature regions in SCD in the context of AD, supporting the notion that individuals with SCD share a similar pattern of brain alterations with patients with mild cognitive impairment (MCI) and dementia due to AD. We conclude that these neuroimaging techniques, particularly multimodal neuroimaging techniques, have great potential for identifying the underlying pathological alterations associated with SCD. More longitudinal studies with larger sample sizes combined with more advanced imaging modeling approaches such as artificial intelligence are still warranted to establish their clinical utility.
Overview
CoChat Summary
TL;DR
This is a narrative review of neuroimaging studies in subjective cognitive decline (SCD) related to Alzheimer’s disease (AD), summarizing molecular, structural, and functional imaging findings. The authors conclude that SCD shows preferential vulnerability in AD-signature regions and that multimodal, longitudinal imaging is needed to clarify heterogeneous findings and improve early detection.
Key findings
- The review included 114 studies published from January 1994 to September 2019, identified through PubMed and ScienceDirect.
- PET studies in SCD reported amyloid pathology prevalence of 12%–43% in a meta-analysis; several studies found higher amyloid positivity than healthy controls and associations between amyloid burden and SCD severity, but results were inconsistent.
- Structural MRI/DTI findings in SCD often showed decreased hippocampal volume, thinner entorhinal/temporal-parietal cortex, and white-matter microstructural disruption; some longitudinal work reported an annual hippocampal decrease of 1.9%.
- Functional imaging frequently implicated the default mode network (DMN) and AD-signature regions, with rs-fMRI, task fMRI, ASL, and EEG/MEG studies showing mixed but recurring abnormalities in connectivity, activation, perfusion, and oscillatory activity.
Methods
- Narrative review design focused on neuroimaging changes in SCD related to AD across PET, MRI, fMRI, ASL, EEG, and MEG.
- Literature search of PubMed and ScienceDirect for English full-text original studies published January 1994–September 2019; included studies required SCD with normal standard neuropsychological performance and no other medical/psychiatric causes.
- The authors synthesized findings qualitatively by imaging modality and discussed heterogeneity, multimodal studies, longitudinal work, and artificial intelligence approaches.
Limitations
- The paper states that longitudinal research is still limited, and most studies are cross-sectional, which does not capture individual trajectories or establish causality.
- The review notes that findings are heterogeneous and inconsistent because of differences in SCD definitions, cohort demographics, and acquisition/quantification methods.
- Evident limitation: this is a review, so it does not report new primary participant data or a formal meta-analysis in the provided text.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
24 Valid · 1 Not valid · 14 Not checked · 50 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SCD is postulated to manifest at a relatively late phase of preclinical AD and is associated with increased risks of AD biomarker abnormalities and future cognitive decline and dementia [2, 4, 6]”
§ Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease > Background
What the sources say
- Supportedcites [2] Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535–62. source
Section 10.4 (page unavailable) places subjective evidence of subtle decline at stage 2, which it describes as similar to stage 3 preclinical AD in the 2011 guidelines. This supports the proposed late-preclinical timing, with the paper’s qualification that subjective complaints are attributable to AD only when the person is in the Alzheimer’s continuum. (LLM, conf=0.87)
- Partly supportedcites [4] Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52. sourceExperimental — accuracy not yet measured
Section 3 says SCD can occur during preclinical AD, and the Introduction discusses subjective decline as a possible indicator of early effects of AD pathology. The paper does not establish that SCD manifests specifically at a relatively late phase of preclinical AD; the Introduction also describes its potential value at a very early disease stage. Page numbers were not available in our copy. (LLM, conf=0.82)
- Supportedcites [6] Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, et al. Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer’s disease dementia. Alzheimers Dement. 2019;15:465–76. source
The Introduction (page not provided) says AD-related changes begin accumulating about 20 years before clinical symptoms and describes SCD as a possible first symptomatic expression of preclinical AD. Together, these support the hedged characterization of SCD as appearing relatively late in the preclinical period. (LLM, conf=0.85)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In 2014, a consensus terminology and a conceptual framework for research on SCD related to AD was proposed by the Subjective Cognitive Decline Initiative (SCD-I) [4].”
§ Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease > Standard terminology and diagnostic criteria The concept of SCD was first introduced in the early 1980s by Reisberg and colleagues to define an early stage of AD and was initially assessed using the Global Deterioration Scale [12]. In recent years, SCD has received various labels, including subjective cognitive complaints, subjective memory complaints, subjective cognitive impairment, subjective memory impairment, subjective memory decline and others [4]. Although the impairment has attracted increasing attention since 2005, SCD research has been hampered by the lack of a common nomenclature, and uniform criteria for defining SCD are not available. Some studies identified SCD with a single question such as “Do you feel you can remember things as well as you used to?”, while other groups assessed SCD with structured questionnaires such as the Mood and Feelings Questionnaire (MFQ) and/or the self-evaluated Everyday Cognition Scale (E-Cog). In 2014, a consensus terminology and a conceptual framework for research on SCD related to AD was proposed by the Subjective Cognitive Decline Initiative (SCD-I) [4]. This framework unified the multiple descriptors into a single term, SCD, and presented a set of features of SCD due to AD, named “SCD-plus”, to facilitate the comparison of study findings, data pooling, meta-analyses, and collaborative multicenter research. These features include onset within 5 years, age at onset ≥ 60 years, concerns regarding feelings of worse performance than other individuals of the same age, confirmation of cognitive decline by an informant, possession of the Apolipoprotein E (ApoE) ɛ4 genotype and the presence of biomarker evidence for AD. Recently, two additional SCD plus features were proposed, including consistent SCD over time and seeking medical help because of SCD [5]. The framework also supports some flexibility in the classification of SCD, but researchers are responsible for explicitly clarifying how they operationalize SCD and why they chose a particular approach. All these efforts help further advance the investigation of SCD related to AD. Only a few longitudinal studies of people with carefully phenotyped SCD have investigated the rate of progression of SCD to dementia due to AD [13, 14]. With clinical advances, the increasing number of memory clinics will facilitate the enrollment of subjects with SCD and increase awareness about SCD and the concept of cognitive protection.
What the sources say
- Supportedcites [4] Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52. source
The Abstract states that the SCD-I working group reached consensus on terminology and a conceptual framework for research on SCD in AD. Section 4, “Aims of the SCD framework,” identifies the proposed features as “SCD plus.” (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“structural and functional brain alterations have been detected in vivo during the asymptomatic stage of AD [8, 9].”
§ Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease > Background
What the sources say
- Partly supportedcites [8] Habib M, Mak E, Gabel S, Su L, Williams G, Waldman A, Wells K, Ritchie K, Ritchie C, O'Brien JT. Functional neuroimaging findings in healthy middle-aged adults at risk of Alzheimer's disease. Ageing Res Rev. 2017;36:88–104. sourceExperimental — accuracy not yet measured
Our copy squarely supports the functional half: the Conclusions state that 'changes as seen on functional imaging are early features of AD', with amyloid PET positive in FAD and ApoE4 carriers 'as early as 15 years before ensuing cognitive decline', MRS metabolite abnormalities 'many years before predicted onset', and hypometabolism/perfusion changes in asymptomatic carriers (Conclusions; Amyloid deposition; Magnetic Resonance Spectroscopy; Cerebral glucose metabolism sections), all in vivo and in presymptomatic/asymptomatic subjects. The structural half is not this paper's own finding: the Introduction states that the authors 'recently surveyed the structural imaging changes in preclinical dementia (Mak et al., 2016a)' as the companion part of a two-part review, and the Conclusions credit the identification of 'vulnerable foci of structural degeneration' to that earlier structural review; here structural atrophy is treated as a later event that functional changes may precede. So the structural-alteration component attributed to this source rests on the separately cited structural review, not on this paper. (LLM, conf=0.72)
- Partly supportedcites [9] Mak E, Gabel S, Mirette H, Su L, Williams GB, Waldman A, Wells K, Ritchie K, Ritchie C, O'Brien J. Structural neuroimaging in preclinical dementia: From microstructural deficits and grey matter atrophy to macroscale connectomic changes. Ageing Res Rev. 2017;35:250–64. sourceExperimental — accuracy not yet measured
Our copy firmly supports the structural half of the claim: the Abstract (p. 4) states that 'a prolonged latency period has been established in AD, with abnormal cerebral changes beginning many years before symptom onset' and that structural imaging identifies early vulnerability in medial temporal lobe, precuneus and white matter tracts; the Conclusion (p. 30) describes structural neuroimaging of presymptomatic individuals identifying cerebral abnormalities 'predating the onset of symptoms as early as up to a decade', with Section 5 (p. 11) and p. 20 listing in vivo atrophic/cortical-thinning and subcortical findings in cognitively normal at-risk groups. The 'functional' alterations half is not this paper's content: the Methods (p. 10) restricted inclusion to structural modalities (T1 MRI and diffusion-weighted MRI), and functional/molecular signals appear only in passing (e.g. hypometabolism credited to Mosconi et al., 2009 on p. 15, amyloid PET discussion on p. 29, fMRI listed as data being collected by the PREVENT study on p. 28). Since the citing sentence carries two references [8, 9], the functional component may belong to the other source, but this one supports only the structural claim. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A meta-analysis reported a prevalence of amyloid pathology among individuals with SCD of 12%-43% [22].”
§ Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease > Positron emission tomography > β-amyloid deposition
What the sources say
- Supportedcites [22] Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. Jama. 2015;313:1924–38. source
The Abstract (Results) reports that amyloid pathology prevalence among patients with subjective cognitive impairment (SCI) rose from 12% at age 50 to 43% at age 90. The Abstract (Objective) identifies the study as an individual-participant-data meta-analysis. The cited range is therefore supported, though it represents age-specific estimates rather than one overall prevalence. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Subjective cognitive decline (SCD), the first clinical manifestation in the AD continuum, is self-experienced decline in cognitive function without evidence of objective cognitive impairment [3–5].”
§ Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease > Background
What the sources say
- Not checked — no full text of the sourcecites [3] Rabin LA, Smart CM, Amariglio RE. Subjective Cognitive Decline in Preclinical Alzheimer's Disease. Annu Rev Clin Psychol. 2017;13:369–96. source
- Partly supportedcites [4] Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844–52. sourceExperimental — accuracy not yet measured
The Introduction describes SCD as a possible indicator of the first effects of AD pathology on cognition, and section 3 says it may be a symptomatic indicator of preclinical AD. But the paper does not establish SCD as the first clinical manifestation in the AD continuum: section 3 says SCD is not present in every case of preclinical AD and can have causes other than AD. Page numbers are not available in our copy. (LLM, conf=0.86)
- Partly supportedcites [5] Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, Rabin L, Rentz DM, Rodriguez-Gomez O, Saykin AJ, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271–8. sourceExperimental — accuracy not yet measured
In “SCD and the Alzheimer’s disease research framework” (page not supplied), the paper places subjective cognitive changes in stage 2, the late preclinical phase of the Alzheimer’s disease continuum. But “Conclusions and future directions” says SCD could be the first symptom of an incipient neurodegenerative disease and is not an indicator of future cognitive decline for most individuals. Calling SCD *the* first clinical manifestation of the AD continuum omits those qualifications. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims · 9 with their cited sources checked
Create a free account to see all 89 claims and to verify the 5 references still open.
- It may state two separate claims as one. 33
- Probably not a substantial claim. 5
- The quote only partly states this claim. 1
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 2×
“Pathological tau deposition represents another key biomarker of AD [45, 46].”
BackgroundA default mode of brain function
Raichle, M. E., MacLeod, A. M., Snyder, A. Z., Powers, W. J., Gusnard, D. A., & Shulman, G. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.2.676 · Cited by 12,190
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Self-citationAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Therefore, consistent with the “amyloid cascade” hypothesis [36], the increase in amyloid levels in ADspecific regions might be associated with SCD, potentially more than 10 years prior to the ensuing cognitive impairment.”
BackgroundFunctional connectivity in the resting brain: a network analysis of the default mode hypothesis
Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0135058100 · Cited by 6,358
The Global Deterioration Scale for assessment of primary degenerative dementia
(1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 4,986
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Jessen, F., Amariglio, R. E., van Boxtel, M., Breteler, M., Ceccaldi, M., Chételat, G., Dubois, B., Dufouil, C., Ellis, K. A., van der Flier, W. M., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.01.001 · Cited by 3,014
Self-citation
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Shandilya, S., Kumar, S., Kumar Jha, N., Kumar Kesari, K., & Ruokolainen, J. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2021.09.005 · Cited by 290
Sheng, C., Yang, K. Y., He, B., Du, W., Cai, Y., & Han, Y. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00977-x · Cited by 93
Self-citationSarraf, S., Sarraf, A., DeSouza, D. D., Anderson, J. A. E., Kabia, M., & The Alzheimer's Disease Neuroimagin, A. D. N. I. (2023) · Brain Sciences · doi:10.3390/brainsci13020260 · Cited by 99
Sharoar, M. G., Palko, S., Ge, Y., Saido, T. C., & Yan, R. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00464-1 · Cited by 78
Metadata
- Authors
- Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y.
- Affiliations
- Capital Medical University (CN)
- Beijing Normal University (CN)
- Southwest University (CN)
- University of Nottingham (GB)
- University of Cologne (DE)
- Corresponding author
- Sun, Yu
- Shu, Ni
- Han, Ying
- Venue
- Molecular Neurodegeneration
- Published
- 2020-09-22
- Volume
- 15
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1750-1326 (ISSN-L)
- PMC
- PMC7507636
- OpenAlex
- W3088567733
- Cited by
- 265
- References
- 214
- Citations by year
- 2026: 32 · 2025: 62 · 2024: 45 · 2023: 49 · 2022: 33 · 2021: 43 · 2020: 1
- FWCI
- 5.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Molecular Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- DZNE Pub (publishedVersion, other-oa)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Apollo
- Funders
- National Key Research and Development Program of China (2016YFC1306300, 2018YFC1312001)
- National Natural Science Foundation of China (61633018, 81671761, 81871425)
- Beijing Municipal Commission of Health and Family Planning (PXM2020_026283_000002)
- Fundamental Research Funds for the Central University (2017XTCX04)
- Beijing Nature Science Foundation (7161009)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
- Keywords
- subjective cognitive decline, preclinical Alzheimer's disease, neuroimaging biomarkers, brain structural changes, brain connectivity, APOE ε4, mild cognitive impairment, dementia, early detection of Alzheimer's disease, age as risk factor
- MeSH terms
- Alzheimer Disease, Female, Humans, Male, Early Diagnosis, Neuroimaging, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. https://app.cochat.ai/papers/10.1186/s13024-020-00395-3
- The paper
- Wang, X., Huang, W., Su, L., Xing, Y., Jessen, F., Sun, Y., Shu, N., & Han, Y. (2020). Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease. Molecular Neurodegeneration. https://doi.org/10.1186/s13024-020-00395-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.